NEW YORK (GenomeWeb News) – Investment bank JP Morgan has upgraded Beckman Coulter's stock to "overweight" from "neutral," due to the firm's long-range earnings forecast.

In mid-December, Beckman Coulter set a preliminary 2010 guidance for adjusted earnings per share of between $4.40 and $4.55, which was just below analysts' consensus estimate of $4.56.

JP Morgan also set a 12-month price target on the stock of $75.

In early Monday trade on the New York Stock Exchange, shares of Beckman Coulter were up around 2 percent at $67.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.